Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
8
×
boston blog main
8
×
boston top stories
life sciences
national blog main
national top stories
biotech
deals
gene editing
san francisco blog main
alnylam pharmaceuticals
clinical trials
crispr
editas medicine
allergan
cynthia collins
drugs
fda
feng zhang
harvard pilgrim health care
hereditary transthyretin amyloidosis
institute for clinical and economic review
new york blog main
patisiran
rna interference
roche
san francisco top stories
startups
vc
abbvie
agios therapeutics
akcea therapeutics
alexion pharmaceuticals
alzheimer's disease
amy schulman
andreas klein
anna greka
barry greene
base editing
biopharma
What
gene
8
×
editing
medicine
medicines
crispr
editas
rna
therapy
drug
experimental
fda
interference
protein
research
roche
therapeutics
abbvie
allergan
alliance
alnylam
approval
approves
aren’t
beam
betting
billion
bio
biopharma
biotech
blessing
bosley
car
cas
caught
causing
cells
ceo
check
clinical
create
Language
unset
Current search:
boston
×
gene
×
" boston blog main "
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
6 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M